Nektar and Bristol-Myers Squibb expand clinical development programme

shutterstock_685347493 (1)-min
Nektar Therapeutics and BMS have entered a revised strategic collaboration agreement to expand the clinical development programme for bempegaldesleukin and Opdivo. Credit: Shutterstock.